PT-141

PT-141 is bremelanotide, a synthetic peptide that acts on melanocortin receptors in the brain. Unlike PDE5 inhibitors such as sildenafil and tadalafil, which work on blood vessels, PT-141 works centrally on the desire and arousal pathway in the hypothalamus.

There is an FDA-approved version, Vyleesi, indicated specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Patients also use bremelanotide outside that approved indication for arousal and libido concerns that haven’t responded to other approaches.

It is dosed as a small subcutaneous injection, taken about 45 minutes before activity. Most patients notice an onset within that window.

PT-141 is dosed as needed, not on a recurring schedule. The 8-doses-per-month limit comes directly from the FDA Vyleesi label, set to limit cumulative exposure and the small risk of pigmentation changes seen with frequent dosing.

Many patients keep a vial on hand and use it on planned occasions, rather than as a daily protocol. Effects on desire and arousal are short-lived and don’t carry over between doses.

Because PT-141 affects blood pressure (transient rise after injection, with a small drop in heart rate), we screen cardiovascular history carefully before starting and avoid it in patients with uncontrolled hypertension or known cardiovascular disease.

PT-141 is often used alongside hormone work. Low libido frequently has a hormonal driver worth ruling out before, or in parallel with, a desire-focused peptide.